PALONOSETRON V PROFILAKTIKE TOShNOTY I RVOTY PRI PROVEDENII VYSOKO I UMERENNO EMETOGENNOY KhIMIOTERAPII


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Nausea and vomiting are the most common complications of chemotherapy. 5-HT3-receptor antagonists are the main group of drugs for the therapy and prevention of nausea and vomiting. Palonosetron® is a new, highly selective, second generation 5-HT3 receptor antagonist, with high affinity for receptor and a long half-life (~ 40 hours). Based on published data of key comparative phase III studies, as well as recommendations MACSS, ESMO, NCCN, ASCO, palonosetron in combination with NK-I-receptor antagonist and dexamethasone is recommended for the prevention of nausea and vomiting during highly emetogenic and moderately emetogenic chemotherapy.

全文:

受限制的访问

作者简介

M. Abramov

K. Lodygina

参考

  1. Hesketh P.J. Defining the emetogenicity of cancer chemotherapy regimens: relevance to clinical practice. Oncologist. 1999; 4: 191-96.
  2. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology-Antiemesis. 2005; 1.
  3. Multinational Association of Supportive Care in Cancer (MASCC). 2004 Perugia Antiemetic Consensus Guidelines. Support Care Cancer. 2005; 13: 77-131
  4. Gregory R.E., Ettinger D.S. 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting: a comparison of their pharmacology and clinical efficacy. Drugs. 1998; 55: 173-89
  5. Johnston D., Latrielle J., Laberge F., et al. Preventing nausea and vomiting during days 2-7 following high-dose cisplatin chemotherapy (HDCP). A study by the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG). Proc. Am. Soc. Clin. Oncol. 1995; 14: 529. (abstr).
  6. Grunberg S.M., Deuson R.R., Mavros P., et al. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer. 2004; 100: 2261-68.
  7. Hickok J.T., Roscoe J.A., Morrow G.R., et al. Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics. A University of Rochester James P. Wilmot Cancer Center Community Clinical Oncology Program Study of 360 Cancer Patients Treated in the Community. Cancer. 2003; 97: 2880-86.
  8. Kaizer L., Warr D., Hoskins P., et al. Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emeto-genic chemotherapy: A phase III trial by the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 1994; 12: 1050-57.
  9. Osoba D., Zee B., Warr D., et al. Effect of postchemotherapy nausea and vomiting on health-related quality of life. Support Care Cancer 1997; 5: 307-13.
  10. Wong E.H.F., Clark R., Leung E., et al. The interaction of RS 25259-197, a potent and selective antagonist, with 5-HT3 receptors, in vitro. Br. J. Pharmacol. 1995; 114: 851-59.
  11. Stoltz R., Cyong J.C., Shah A., et al. Pharmacokinetic and safety evaluation of palonosetron, a 5-hydroxytryptamine-3 receptor antagonist, in US and Japanese healthy subjects. J. Clin. Pharmacol. 2004; 44: 520-31.
  12. Roscoe J.A., et al. Patient expectation is a strong predictor of severe nausea after chemotherapy. Cancer. 2004; 101: 2701.
  13. Gralla R., Lichinitser M., Van Der Vegt S., et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol. 2003; 14(10): 1570-77.
  14. Eisenberg P., Figueroa-Vadillo J., Zamora R., et al. 99-04 Palonosetron Study Group Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III., single-dose trial versus dolasetron. Cancer. 2003; 98(11): 2473-82.
  15. Aapro M.S., Bertoli L., Lordic F., et al. Palonosetron is effective in preventing acute and delayed chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy [abstract A-17]. Support Care Cancer. 2003; 11(6): 391.
  16. Clark O., Engel T., Clark L., et al. Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatments: Systematic review and meta-analysis. J. Clin. Oncol. 2009; 27(suppl): abstr e20620.
  17. Efficacy of palonosetron-based antiemetic prophylaxis in breast cancer patients receiving anthracycline-containing adjuvant chemotherapy: A survey in 41 German gyneco-oncology practices. J. Clin. Oncol. 2012; 30(suppl): abstr. e19540.
  18. Giralt J., et al. Oncol. Pharm Pract. September 4, 2013 1078155213502103.
  19. Deauna-Limayo D., Aljitawi O.S., Siddhartha Ganguly, et al. Combined use of multiday palonosetron with aprepitant and low-dose dexamethasone in prevention of nausea and emesis among patients with multiple myeloma and lymphoma undergoing autologous hematopoietic stem cell transplant: A pilot study Bernardo G., Palumbo R., Frascaroli M., Bernardo A., Losurdo A., Poggi G., Teragni C., Albanese D., Amatu A., Strada M.R. Palonosetron compared to ondansetron in the prevention of chemotherapy-induced nausea and vomiting: Activity, safety, and cost-effectiveness evaluation. J. Clin. Oncol. 2009; 27(suppl): abstr. e20573.
  20. Kim S.K., Choi Y.J., Seol Y.M., Song M.G., Shin H.J., Chung J., Cho G.J. Efficacy of palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with stomach cancer receiving FOLFOX4 regimen. J. Clin. Oncol. 2011; 29(suppl): abstr e19580.
  21. Blazer M.A., Reardon J., Efries D., et al. Antiemetic control of palonosetron in patients with gastrointestinal cancer receiving a fluoropyrimidine-based regimen containing either irinotecan or oxaliplatin. J. Clin. Oncol. 2011; 29(suppl): abstr. 9079.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2014
##common.cookie##